Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.45
NPSP's Cash to Debt is ranked higher than
63% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. NPSP: 1.45 )
NPSP' s 10-Year Cash to Debt Range
Min: 0.22   Max: 96771
Current: 1.45

0.22
96771
Equity to Asset 0.45
NPSP's Equity to Asset is ranked higher than
60% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. NPSP: 0.45 )
NPSP' s 10-Year Equity to Asset Range
Min: -1.62   Max: 0.99
Current: 0.45

-1.62
0.99
F-Score: 4
Z-Score: 8.50
M-Score: -1.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 7.84
NPSP's Operating margin (%) is ranked higher than
85% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. NPSP: 7.84 )
NPSP' s 10-Year Operating margin (%) Range
Min: -4401.9   Max: 47.29
Current: 7.84

-4401.9
47.29
Net-margin (%) 1.08
NPSP's Net-margin (%) is ranked higher than
81% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. NPSP: 1.08 )
NPSP' s 10-Year Net-margin (%) Range
Min: -4031.2   Max: 30.05
Current: 1.08

-4031.2
30.05
ROE (%) 2.03
NPSP's ROE (%) is ranked higher than
83% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. NPSP: 2.03 )
NPSP' s 10-Year ROE (%) Range
Min: -336.52   Max: 15.8
Current: 2.03

-336.52
15.8
ROA (%) 0.74
NPSP's ROA (%) is ranked higher than
83% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. NPSP: 0.74 )
NPSP' s 10-Year ROA (%) Range
Min: -63.13   Max: 14.73
Current: 0.74

-63.13
14.73
ROC (Joel Greenblatt) (%) 31.40
NPSP's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. NPSP: 31.40 )
NPSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3684.06   Max: 273.86
Current: 31.4

-3684.06
273.86
Revenue Growth (%) 1.30
NPSP's Revenue Growth (%) is ranked higher than
77% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. NPSP: 1.30 )
NPSP' s 10-Year Revenue Growth (%) Range
Min: -47.8   Max: 90.4
Current: 1.3

-47.8
90.4
EBITDA Growth (%) -65.80
NPSP's EBITDA Growth (%) is ranked higher than
52% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. NPSP: -65.80 )
NPSP' s 10-Year EBITDA Growth (%) Range
Min: -75.6   Max: 87.7
Current: -65.8

-75.6
87.7
EPS Growth (%) -36.20
NPSP's EPS Growth (%) is ranked higher than
60% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NPSP: -36.20 )
NPSP' s 10-Year EPS Growth (%) Range
Min: -86.9   Max: 278
Current: -36.2

-86.9
278
» NPSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NPSP Guru Trades in Q3 2013

Jim Simons Sold Out
Columbia Wanger 4,445,000 sh (-14.63%)
RS Investment Management 1,439,745 sh (-26.92%)
Pioneer Investments 448,811 sh (-31.82%)
Steven Cohen 105,901 sh (-47.55%)
» More
Q4 2013

NPSP Guru Trades in Q4 2013

Steven Cohen 123,245 sh (+16.38%)
RS Investment Management 1,536,945 sh (+6.75%)
Pioneer Investments 369,214 sh (-17.74%)
Columbia Wanger 3,635,300 sh (-18.22%)
» More
Q1 2014

NPSP Guru Trades in Q1 2014

Jim Simons 23,500 sh (New)
Mariko Gordon 14,828 sh (New)
John Burbank 6,756 sh (New)
Steven Cohen 260,800 sh (+111.61%)
RS Investment Management 1,529,445 sh (-0.49%)
Columbia Wanger 2,771,000 sh (-23.78%)
Pioneer Investments 274,256 sh (-25.72%)
» More
Q2 2014

NPSP Guru Trades in Q2 2014

Eric Mindich 408,141 sh (New)
Louis Moore Bacon 25,000 sh (New)
Joel Greenblatt 12,104 sh (New)
Mariko Gordon 15,986 sh (+7.81%)
Louis Moore Bacon 30,000 sh (unchged)
John Burbank Sold Out
Jim Simons Sold Out
RS Investment Management Sold Out
Pioneer Investments 253,897 sh (-7.42%)
Columbia Wanger 1,736,720 sh (-37.33%)
» More
» Details

Insider Trades

Latest Guru Trades with NPSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.01%$23.38 - $35.37 $ 29.081%12104
John Burbank 2014-06-30 Sold Out 0.01%$23.38 - $35.37 $ 29.081%0
Mariko Gordon 2014-03-31 New Buy0.02%$27.55 - $39.06 $ 29.08-16%14828
John Burbank 2014-03-31 New Buy0.01%$27.55 - $39.06 $ 29.08-16%6756
George Soros 2011-12-31 Sold Out 0.06%$4.97 - $7.76 $ 29.08370%0
George Soros 2011-09-30 Add 98.31%0.03%$6.11 - $10.18 $ 29.08264%545349
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 1077.20
NPSP's P/E(ttm) is ranked higher than
81% of the 987 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NPSP: 1077.20 )
NPSP' s 10-Year P/E(ttm) Range
Min: 8.92   Max: 1384.8
Current: 1077.2

8.92
1384.8
P/B 22.20
NPSP's P/B is ranked lower than
58% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. NPSP: 22.20 )
NPSP' s 10-Year P/B Range
Min: 9.18   Max: 38.23
Current: 22.2

9.18
38.23
P/S 14.50
NPSP's P/S is ranked higher than
68% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. NPSP: 14.50 )
NPSP' s 10-Year P/S Range
Min: 1.6   Max: 136.3
Current: 14.5

1.6
136.3
EV-to-EBIT 199.29
NPSP's EV-to-EBIT is ranked higher than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NPSP: 199.29 )
NPSP' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 38665.5
Current: 199.29

4.5
38665.5
Current Ratio 5.90
NPSP's Current Ratio is ranked higher than
82% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. NPSP: 5.90 )
NPSP' s 10-Year Current Ratio Range
Min: 0.52   Max: 96.48
Current: 5.9

0.52
96.48
Quick Ratio 5.14
NPSP's Quick Ratio is ranked higher than
80% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. NPSP: 5.14 )
NPSP' s 10-Year Quick Ratio Range
Min: 0.52   Max: 96.48
Current: 5.14

0.52
96.48

Valuation & Return

vs
industry
vs
history
Price/Net Cash 264.37
NPSP's Price/Net Cash is ranked higher than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 125.18 vs. NPSP: 264.37 )
NPSP' s 10-Year Price/Net Cash Range
Min: 1.76   Max: 2993
Current: 264.37

1.76
2993
Price/Net Current Asset Value 51.02
NPSP's Price/Net Current Asset Value is ranked higher than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 57.00 vs. NPSP: 51.02 )
NPSP' s 10-Year Price/Net Current Asset Value Range
Min: 1.76   Max: 262.5
Current: 51.02

1.76
262.5
Price/Tangible Book 30.61
NPSP's Price/Tangible Book is ranked higher than
63% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. NPSP: 30.61 )
NPSP' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 51.31
Current: 30.61

1.6
51.31
Price/Median PS Value 2.61
NPSP's Price/Median PS Value is ranked higher than
70% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NPSP: 2.61 )
NPSP' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 64.42
Current: 2.61

0.31
64.42
Price/Graham Number 44.74
NPSP's Price/Graham Number is ranked higher than
86% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NPSP: 44.74 )
NPSP' s 10-Year Price/Graham Number Range
Min: 1.33   Max: 51.05
Current: 44.74

1.33
51.05
Earnings Yield (Greenblatt) 0.50
NPSP's Earnings Yield (Greenblatt) is ranked lower than
57% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NPSP: 0.50 )
NPSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 22.1
Current: 0.5

0.1
22.1
Forward Rate of Return (Yacktman) -1.00
NPSP's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. NPSP: -1.00 )
NPSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -113.8   Max: -1
Current: -1

-113.8
-1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPM.Germany
NPS Pharmaceuticals, Inc is a biopharmaceutical company, which is focused on the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. The Company's clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: GATTEX(tm) (teduglutide) and Natpara (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). SBS is a highly disabling condition that results from surgical resection, congenital defect or disease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Natpara is the Company's recombinant full-length human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company is currently advancing registration studies for GATTEX and Natpara. The Company has collaborations or royalty agreements with a number of pharmaceutical companies. 'NPS, 'NPS Pharmaceuticals', 'GATTEX', and 'PREOS' are the Company's trademarks. The Company has competitors in both the U.S. and internationally including multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of its competitors have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these fields.
» More Articles for NPSP

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN Sep 29 2013 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
NPS Pharmaceuticals Reports Second Quarter 2009 Financial Results; Two Phase 3 Registration Programs Aug 06 2009 
NPS Pharmaceuticals to Report Second Quarter Financial Results on August 6, 2009 Aug 03 2009 
NPS Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2009 
George Soros Buys Partner Communications Co. Ltd, CR Bard Inc., Valley Forge Scientific Corp., Sells Aug 15 2006 

More From Our Partners
Benzinga's Weekend M&A Chatter Oct 19 2014 - BENZINGA

More From Other Websites
Street Talk: Lorillard gets upgraded Oct 24 2014
Shire makes $1.5bn profit from collapsed AbbVie deal Oct 24 2014
Jilted Shire raises guidance again after earnings jump Oct 24 2014
Perilous Reversal Watch: NPS Pharmaceuticals (NPSP) Oct 24 2014
NPS Pharma says FDA extends review of Natpara Oct 23 2014
NPS Pharma says FDA extends review of Natpara Oct 23 2014
PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015 Oct 23 2014
4:34 pm NPS Pharm: PDUFA action date for Natpara BLA extended three months to January 24, 2015 Oct 23 2014
Will NPS Pharma (NPSP) Continue to Surge Higher? Oct 22 2014
Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential Oct 20 2014
NPS Pharma to Present at Leerink Partners Rare Disease Roundtable Sep 24 2014
NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote Sep 15 2014
Terex Falls After Lowered Earnings Forecast; Avanir Pharmaceuticals Shares Surge Sep 15 2014
NPS Pharma Enters Cautionary Phase of the FDA Approval Process Sep 15 2014
NPS Pharma Hormone Drug Wins Shaky Endorsement From FDA Panel Sep 15 2014
[$$] FDA Panel Backs NPS Hormone Drug Sep 12 2014
FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of... Sep 12 2014
U.S. FDA panel recommends approval of NPS hormone replacement drug Sep 12 2014
NPS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 12 2014
NPS Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara® Biologics License... Sep 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK